Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sana Biotechnology, Inc

Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at December 2024 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at September 2024 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at May and June 2024 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Pricing of Upsized Public Offering
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Proposed Public Offering of Common Stock
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at November and December 2023 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at September 2023 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.